1. ALS Association. Facts you should know. www.alsa.org/about-als/facts-you-should-know.html. Accessed May 30, 2012.
2. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Neurologist. 2005;11(5):257-270.
3. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
4. Yoshida M. Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum. Neuropathology. 2004;24(1):87-102.
5. Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623-627.
6. National Institute of Neurological Disorders and Stroke, NIH. Motor neuron diseases fact sheet. www.ninds.nih.gov/disorders/motor_neuron_diseases/detail_motor_neuron_diseases.htm. Accessed May 30, 2012.
7. Tartaglia MC, Rowe A, Findlater K. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007;64(2):232-236.
8. Strowd RE, Cartwright MS, Okun MS, et al. Pseudobulbar affect: prevalence and quality of life impact in movement disorders. J Neurol. 2010;257(8):1382-1387.
9. Beghi E, Logroscino G, Chiò A, et al; EURALS Consortium. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta. 2006;1762(11-12):1150-1157.
10. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557-570.
11. Weisskopf MG, Morozova N, O’Reilly EJ, et al. Prospective study of chemical exposures and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):558-561.
12. ALS Association. ALS in the military: unexpected consequences of military service (2011). www.alsa.org/assets/pdfs/advocacy/als_military_paper.pdf. Accessed May 22, 2012.
13. Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003;61(6):742-749.
14. Horner RD, Grambow SC, Coffman DJ, et al. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. Neuroepidemiology. 2008;31(1):28-32.
15. Wang H, O’Reilly EJ, Weisskopf MG, et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol. 2011;68(2):207-213.
16. Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2008;70(21):1984-1990.
17. Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208-1211.
18. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668-1672.
19. Pioro EP, Majors AAW, Mitsumoto H, et al. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology. 1999;53(1):71-79.
20. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942-1959.
21. Paubel A, Violette J, Amy M, et al. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch Neurol. 2008;65(10):1333-1336.
22. Neusch C, Bähr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve. 2007;35(6):712-724.
23. Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve. 2010;41(12):161-165.
24. Shoesmith CL, Findlater K, Rowe A, Strong MJ. Progression of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry. 2007;78(6):629-631.
25. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol. 2000;57(8):1171-1176.
26. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994-1003.
27. Chen R, Grand’Maison F, Strong MJ, et al. Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study. J Neurol Neurosurg Psychiatry. 1996;60(4):455-458.
28. Gautier G, Verscheuren A, Monnier A, et al. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. Amyotroph Lateral Scler. 2010;11(4):379-382.
29. Hasan A, Saxena AB, Ahmed SM, Swamy TLN. Amyotrophic lateral sclerosis presenting with orthopnea in a patient with COPD and obstructive sleep apnea. J Med All Sci. 2011;1(1):46-49.
30. Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79(1):33-37.
31. Brown RH Jr. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Fauci AS, Braunwald E, Kasper DL, ed al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical; 2008:2572-2576.
32. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol. 1998;24(2):104-117.
33. Atsumi T, Miyatake T. Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis. Acta Neuropathol. 1987;73(1):25-31.
34. Shimizu T, Komori T, Kato S, et al. Masseter inhibitory reflex in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(4):189-195.
35. Rosen H. Dextromethorphan/quinidine sulfate (Zenvia) for pseudobulbar affect. Drugs Today (Barc). 2008;44(9):661-668.
36. Rippon GA, Scarmeas N, Gordon PH, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol. 2006;63(3):345-352.
37. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65(1):62-67.
38. Vignola A, Guzzo A, Calvo A, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol. 2008;15(11):1231-1236.
39. Fang F, Valdimarsdóttir U, Fürst CJ, et al. Suicide among patients with amyotrophic lateral sclerosis. Brain. 2008;131(pt 10):2729-2733.
40. Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(4):383-388.
41. Turner MR, Modo M. Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opin Med Diagn. 2010;4(6):483-496.
42. Cirillo M, Esposito F, Tedeschi G, et al. Widespread microstructural white matter involvement in amyotrophic lateral sclerosis: a whole-brain DTI study. AJNR Am J Neuroradiol. 2012 Feb 2. [Epub ahead of print]
43. Canu E, Agosta F, Riva N, et al. The topography of brain microstructural damage in amyotrophic lateral sclerosis assessed using diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2011;32(7):1307-1314.
44. Baek WS, Desai NP. ALS: pitfalls in the diagnosis. Pract Neurol. 2007;7(2):74-81.
45. ALS Association. Criteria for the diagnosis of ALS. www.alsa.org/als-care/resources/publica tions-videos/factsheets/criteria-for-diagnosis.html. Accessed May 31, 2012.
46. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503.
47. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.
48. Waragai M. MRI and clinical features of amyotrophic lateral sclerosis. Neuroradiology. 1997;39(12):847-851.
49. Thorpe JW, Moseley IF, Hawkes CH, et al. Brain and spinal cord MRI in motor neuron disease. J Neurol Neurosurg Psychiatry. 1996; 61(3):314-317.
50. Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993;189 (3):843-846.
51. Piao YS, Wakabayashi K, Kakita A, et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol. 2003;13(1):10-22.
52. Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925-2004. J Neurol Neurosurg Psychiatry. 2010;81(10):1144-1146.
53. del Aguila MA, Longstreth WT Jr, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813-819.
54. Matuz T, Birbaumer N, Hautzinger M, Kübler A. Coping with amyotrophic lateral sclerosis: an integrative view. J Neurol Neurosurg Psychiatry. 2010;81(8):893-898.
55. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012 Mar 14;3:CD001447.
56. Handy CR, Krudy C, Boulis N, Federici T. Pain in amyotrophic lateral sclerosis: a neglected aspect of disease. Neurol Res Int. 2011; 2011:403808. Epub 2011 May 3.
57. McClelland S 3rd, Bethoux FA, Boulis NM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37(3):396-398.
58. Andersen PM, Borasio GD, Dengler R, et al; EALSC Working Group. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. Amyotroph Lateral Scler. 2007;8(4):195-213.
59. Rabkin JG, Gordon PH, McElhiney M, et al. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009;39(3):297-303.
60. Kühnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366-374.
61. Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004030.
62. Lechtzin N, Scott Y, Busse AM, et al. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler. 2007;8(3):185-188.
63. Annane D, Orlikowski D, Chevret S, et al. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001941.
64. Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004427.
65. Onders RP, Elmo MJ, Khansarinia S, et al. Complete worldwide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients. Surg Endosc. 2009;23(7):1433-1440.
66. Onders RP, Carlin AM, Elmo M, et al. Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg. 2009;197(3):386-390.
67. US Food and Drug Administration. Medical devices: NeuRx Diaphragm Pacing System™—H100006. www.fda.gov/MedicalDevices/Prod uctsandMedicalProcedures/DeviceApprovalsand Clearances/Recently-ApprovedDevices/ucm278684.htm. Accessed May 31, 2012.
68. Rabkin JG, Wagner GJ, Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med. 2000; 62(2):271-279.
69. Chiò A, Gauthier A, Vignola A, et al. Caregiver time use in ALS. Neurology. 2006;67(5):902-904.